188 related articles for article (PubMed ID: 32183586)
1. Safety of two-hour intermittent intravenous infusions of tacrolimus in the allogeneic hematopoietic stem cell transplantation unit.
Bacopoulos AJ; Ho L; Yang A; Ng P; Dara C; Loach D; Deotare U; Michelis FV; Viswabandya A; Kim DD; Lipton JH; Messner HA; Thyagu S
J Oncol Pharm Pract; 2021 Jan; 27(1):33-39. PubMed ID: 32183586
[TBL] [Abstract][Full Text] [Related]
2. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation.
Woo M; Przepiorka D; Ippoliti C; Warkentin D; Khouri I; Fritsche H; Körbling M
Bone Marrow Transplant; 1997 Dec; 20(12):1095-8. PubMed ID: 9466284
[TBL] [Abstract][Full Text] [Related]
3. Interdisciplinary implementation of tacrolimus intravenous standard concentration in hematopoietic stem cell transplantation recipients.
Shank BR; Deaver M; Baker A; Myers AL; Zhang YP; Anderegg B; Bassett R; Westmoreland M
J Oncol Pharm Pract; 2018 Jul; 24(5):365-370. PubMed ID: 28554241
[TBL] [Abstract][Full Text] [Related]
4. Twice daily i.v. bolus tacrolimus infusion for GVHD prophylaxis in children undergoing stem cell transplantation.
Skeens M; Pai V; Garee A; Termuhlen AM; Bajwa RP; Gross TG; Soni S
Bone Marrow Transplant; 2012 Nov; 47(11):1415-8. PubMed ID: 22484323
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.
Furlong T; Storb R; Anasetti C; Appelbaum FR; Deeg HJ; Doney K; Martin P; Sullivan K; Witherspoon R; Nash RA
Bone Marrow Transplant; 2000 Nov; 26(9):985-91. PubMed ID: 11100278
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with optimized tacrolimus dosing in hematopoietic stem cell transplantation.
Butts AR; Brown VT; McBride LD; Bolaños-Meade J; Bryk AW
J Oncol Pharm Pract; 2016 Apr; 22(2):275-83. PubMed ID: 25802301
[TBL] [Abstract][Full Text] [Related]
7. Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors.
Mori T; Kato J; Shimizu T; Aisa Y; Nakazato T; Yamane A; Ono Y; Kunimoto H; Okamoto S
Biol Blood Marrow Transplant; 2012 Feb; 18(2):229-34. PubMed ID: 21708109
[TBL] [Abstract][Full Text] [Related]
8. Transitioning tacrolimus to sirolimus in allogeneic hematopoietic cell transplantation.
Arrabi L; Jan A; Hosing C; Milton DR; Yeh J
Eur J Haematol; 2021 Dec; 107(6):634-641. PubMed ID: 34431142
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders.
Ringdén O; Remberger M; Dahllöf G; Garming-Legert K; Karlsson H; Svenberg P; Uhlin M; Uzunel M; Mattsson J
Eur J Haematol; 2011 Dec; 87(6):503-9. PubMed ID: 22974354
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation.
Jacobson P; Uberti J; Davis W; Ratanatharathorn V
Bone Marrow Transplant; 1998 Aug; 22(3):217-25. PubMed ID: 9720734
[TBL] [Abstract][Full Text] [Related]
11. Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation.
Yamashita T; Fujishima N; Miura M; Niioka T; Abumiya M; Shinohara Y; Ubukawa K; Nara M; Fujishima M; Kameoka Y; Tagawa H; Hirokawa M; Takahashi N
Cancer Chemother Pharmacol; 2016 Jul; 78(1):111-8. PubMed ID: 27217047
[TBL] [Abstract][Full Text] [Related]
12. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.
Törlén J; Ringdén O; Garming-Legert K; Ljungman P; Winiarski J; Remes K; Itälä-Remes M; Remberger M; Mattsson J
Haematologica; 2016 Nov; 101(11):1417-1425. PubMed ID: 27662016
[TBL] [Abstract][Full Text] [Related]
13. Low incidence of acute graft-versus-host disease with short-term tacrolimus in haploidentical hematopoietic stem cell transplantation.
Gao L; Liu J; Zhang Y; Chen X; Gao L; Zhang C; Liu Y; Kong P; Zhong J; Sun A; Du X; Su Y; Li H; Liu H; Peng X; Zhang X
Leuk Res; 2017 Jun; 57():27-36. PubMed ID: 28273549
[TBL] [Abstract][Full Text] [Related]
14. Twice-daily intravenous bolus tacrolimus infusion: A safe and effective regimen for graft-versus-host disease prophylaxis.
Hashmi H; Bhandari S; Kumar R; Tripathi P; Rhodes JB; Figg L; Baize T; Krem MM; Hegazi M; Emmons R
Hematol Oncol Stem Cell Ther; 2020 Dec; 13(4):232-237. PubMed ID: 32413417
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation.
Yanik G; Levine JE; Ratanatharathorn V; Dunn R; Ferrara J; Hutchinson RJ
Bone Marrow Transplant; 2000 Jul; 26(2):161-7. PubMed ID: 10918426
[TBL] [Abstract][Full Text] [Related]
16. Comparison of continuous and twice-daily infusions of cyclosporine A for graft-versus-host-disease prophylaxis in pediatric hematopoietic stem cell transplantation.
Umeda K; Adachi S; Tanaka S; Ogawa A; Hatakeyama N; Kudo K; Sakata N; Igarashi S; Ohshima K; Hyakuna N; Chin M; Goto H; Takahashi Y; Azuma E; Koh K; Sawada A; Kato K; Inoue M; Atsuta Y; Takami A; Murata M;
Pediatr Blood Cancer; 2015 Feb; 62(2):291-298. PubMed ID: 25307105
[TBL] [Abstract][Full Text] [Related]
17. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
18. Initial tacrolimus weight-based dosing strategy in allogeneic hematopoietic stem-cell transplantation.
Soskind R; Xiang E; Lewis T; Al-Homsi AS; Papadopoulos J; Cirrone F
J Oncol Pharm Pract; 2021 Sep; 27(6):1447-1453. PubMed ID: 32957861
[TBL] [Abstract][Full Text] [Related]
19. A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis.
Piñana JL; Perez-Pitarch A; Garcia-Cadenas I; Barba P; Hernandez-Boluda JC; Esquirol A; Fox ML; Terol MJ; Queraltó JM; Vima J; Valcarcel D; Ferriols-Lisart R; Sierra J; Solano C; Martino R
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1177-1185. PubMed ID: 28396159
[TBL] [Abstract][Full Text] [Related]
20. Calcineurin inhibitor-induced irreversible neuropathic pain after allogeneic hematopoietic stem cell transplantation.
Fujii N; Ikeda K; Koyama M; Aoyama K; Masunari T; Kondo E; Matsuzaki T; Mizobuchi S; Hiraki A; Teshima T; Shinagawa K; Ishimaru F; Tanimoto M
Int J Hematol; 2006 Jun; 83(5):459-61. PubMed ID: 16787880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
